-transparent.png){kind=logo}
To test the hypothesis that lithium is a general inhibitor of hormone-activated adenylate cyclase, we infuse parathyroid hormone (PTH) into human subjects prior to and during lithium carbonate administration. PTH infusion caused a significant increase in urinary cyclic AMP and urinary phosphate excretion. There was no significant difference in these responses in the lithium compared to the control period. In four patients with primary hyperparathyroidism, lithium had no significant effect on serum calcium or phosphate or on tubular reabsorption of phosphate. The data do not substantiate the hypothesis that lithium (at therapeutic concentrations) is a general inhibitor of hormonally-activated adenylate cyclase, nor do they support its potential clinical utility in primary hyperparthyroidism.
A M Spiegel, and
R H Gerner, and
D L Murphy, and
G D Aurbach
December 1980,
Endocrinology,
A M Spiegel, and
R H Gerner, and
D L Murphy, and
G D Aurbach
August 1974,
The Journal of clinical endocrinology and metabolism,
A M Spiegel, and
R H Gerner, and
D L Murphy, and
G D Aurbach
February 1984,
Lancet (London, England),
A M Spiegel, and
R H Gerner, and
D L Murphy, and
G D Aurbach
May 1984,
Clinical science (London, England : 1979),
A M Spiegel, and
R H Gerner, and
D L Murphy, and
G D Aurbach
April 1977,
American journal of surgery,
A M Spiegel, and
R H Gerner, and
D L Murphy, and
G D Aurbach
November 1976,
Pflugers Archiv : European journal of physiology,
A M Spiegel, and
R H Gerner, and
D L Murphy, and
G D Aurbach
September 1995,
Bone,
A M Spiegel, and
R H Gerner, and
D L Murphy, and
G D Aurbach
April 1975,
The Tohoku journal of experimental medicine,
A M Spiegel, and
R H Gerner, and
D L Murphy, and
G D Aurbach
July 1972,
Pediatrics,
A M Spiegel, and
R H Gerner, and
D L Murphy, and
G D Aurbach
January 1983,
General and comparative endocrinology,
